Viridian Therapeutics Inc. (NASDAQ:VRDN)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
VRDN Weekly Chart

Old Forum Content for VRDN

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $VRDN contiunes on a nice path, most recently (last month-plus) 8d-13dEMA support. Long.
  • Onthemark: @woodman $VRDN Been in this as well, NH today
  • woodman: $VRDN - added
  • woodman: $VRDN has been working very well. Another strong biotech. (I probably have to many now....)
  • woodman: $XBI $IBB - current bio holdings: $ZBIO $CELC $BBIO $INSM $NKTR (and a small bit of $VKTX and $GPCR). Kicking myself for not buying $VRDN and $AXSM which were on my same shopping list (along with these others) months ago.
  • Motorman: @woodman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM IBD wrote a piece on $CELC Nov 10. Did not take a piece, now up 25% in 2 weeks. Missed it. More left in tank?
  • joelsg1: @woodman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM Awaiting clinical trial results for $AXSM Alzheimers and depression drugs due this Q-L.
  • woodman: @joelsg1 $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM - I'm not fond of biotech binary events. Too many scars. Alzheimer's is a tough area, but I'll read up on it.
  • woodman: @Motorman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM - I don't think I saw the IBD article, but I bought CELC back right around then. I had it in the $50s, but didn't hang on, unfortunately. Bought it back in the mid $70s.
Visit the Trading Forum to join in the discussion.
Stock Price $13.93
Change -26.06%
Volume 10,939,100

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Request Video of VRDN
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!